- 全部删除
您的购物车当前为空
Adebrelimab (SHR-1316) 是一种人源化靶向 PD-L1 的单克隆抗体,具有抗肿瘤活性,可用于研究实体肿瘤。

为众多的药物研发团队赋能,
让新药发现更简单!
Adebrelimab (SHR-1316) 是一种人源化靶向 PD-L1 的单克隆抗体,具有抗肿瘤活性,可用于研究实体肿瘤。
| 规格 | 价格 | 库存 | 数量 |
|---|---|---|---|
| 1 mg | ¥ 2,480 | In stock | |
| 5 mg | ¥ 5,860 | In stock | |
| 10 mg | ¥ 7,890 | In stock | |
| 25 mg | ¥ 11,700 | In stock | |
| 50 mg | ¥ 15,800 | In stock |
Adebrelimab 相关产品
| 产品描述 | Adebrelimab (SHR-1316) is a humanized monoclonal antibody targeting PD-L1 with antitumor activity for the study of solid tumors. |
| 体外活性 | Adebrelimab (0.06-1 mg/mL;处理 48 小时)可显著抑制 SK-BR-3 和 AU565 细胞的增殖、迁移及侵袭能力。[1] |
| 体内活性 | Adebrelimab (200 μg;每周给药 3 次;持续 21 天)对肿瘤生长表现出显著的抑制作用。[1] |
| 别名 | 阿得贝利单抗, SHR-1316, SHR1316, HTI-1316, HTI1316, HTI-1088, HTI1088 |
| CAS No. | 2247114-85-6 |
| 颜色 | Transparent |
| 物理性状 | Liquid |
| 存储 | store at low temperature | -20°C for 1 year | Shipping with blue ice/Shipping at ambient temperature. |
评论内容